ALX-0681 regulatory update

EMEA's Committee for Orphan Medicinal Products (COMP) issued a positive opinion to grant Orphan Drug designation for Ablynx's ALX-0681 to treat thrombotic thrombocytopenic purpura. The nanobody target...